One step closer to influenza vaccine inclusiveness
- PMID: 33236432
- PMCID: PMC7753274
- DOI: 10.1111/pai.13338
One step closer to influenza vaccine inclusiveness
Abstract
Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live-attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a "universal vaccine" strategy.
Keywords: asthma; children; immunodeficiency; influenza vaccine; pregnancy; universal vaccine.
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Conflict of interest statement
All authors reported no conflicts of interest.
References
-
- Committee on Infectious Diseases . Recommendations for prevention and control of influenza in children, 2019–2020. Pediatrics. 2019;144:e20192478. - PubMed
-
- Schwarze J, Openshaw P, Jha A, et al. Influenza burden, prevention, and treatment in asthma–a scoping review by the EAACI Influenza in asthma task force. Allergy. 2018;73:1151‐1181. - PubMed
